申请人:Glaxo Laboratories Limited
公开号:US04062955A1
公开(公告)日:1977-12-13
Compounds of the general formula: ##STR1## wherein the groups CHR.sup.1 NR.sup.2 R.sup.3 and CHR.sup.4 NR.sup.5 R.sup.6 may be the same or different and where the group CHR.sup.4 NR.sup.5 R.sup.6 is in either the 1 or the 3 position and R.sup.1 and R.sup.4 independently represent a hydrogen atom or an aryl group; R.sup.2, r.sup.3, r.sup.5 and R.sup.6 which may be the same or different are each a hydrogen atom or an alkyl group or an aryl group both of which may in turn be substituted by one or more hydroxy, alkoxy, acyloxy, dialkylamino or aryl groups or the groups --NR.sup.2 R.sup.3 and/or NR.sup.5 R.sup.6 represent a heterocyclic ring containing one or more hetero atoms and which ring may optionally be substituted by an alkyl, aryl or aralkyl group and in which either aromatic ring of the naphthalene nucleus may be further substituted; with the proviso that when R.sup.1, R.sup.4, R.sup.2 and R.sup.5 are hydrogen, then R.sup.3 and R.sup.6 cannot both be benzyl, when the second substituent is in the 1 position; and when R.sup.1 and R.sup.4 are hydrogen, then R.sup.2, R.sup.3, R.sup.5 and R.sup.6 cannot all be methyl when the second substituent is in the 1 position; and when R.sup.1 and R.sup.4 are hydrogen, then R.sup.2 and R.sup.3 and R.sup.5 and R.sup.6 together with the nitrogen atom cannot both be piperidino when the second substituent is in the 3 position and the naphthalene nucleus is further substituted by hydroxy in the 1 and 4 positions; and pharmaceutically acceptable salts of such compounds; and hydrates of such compounds and such salts. The compounds have activity on the central nervous system in particular as analgesics.
通式为## STR1 ##的化合物,其中CHR.sup.1 NR.sup.2 R.sup.3和CHR.sup.4 NR.sup.5 R.sup.6基团可以相同也可以不同,且CHR.sup.4 NR.sup.5 R.sup.6基团位于1或3位置,R.sup.1和R.sup.4分别代表氢原子或芳基基团; R.sup.2,r.sup.3,r.sup.5和R.sup.6可以相同也可以不同,分别是氢原子或烷基或芳基基团,这些基团又可以被一个或多个羟基,烷氧基,酰氧基,二烷基氨基或芳基基团所取代,或者--NR.sup.2 R.sup.3和/或NR.sup.5 R.sup.6代表含有一个或多个杂原子的杂环,该环可以被烷基,芳基或芳基烷基所取代,并且萘核的任一芳环可以进一步取代; 前提是当R.sup.1,R.sup.4,R.sup.2和R.sup.5为氢时,当第二取代基位于1位置时,R.sup.3和R.sup.6不能同时为苄基; 当R.sup.1和R.sup.4为氢时,当第二取代基位于1位置时,R.sup.2,R.sup.3,R.sup.5和R.sup.6不能都为甲基; 当R.sup.1和R.sup.4为氢时,当第二取代基位于3位置且萘核在1和4位置进一步取代为羟基时,R.sup.2和R.sup.3和R.sup.5和R.sup.6连同氮原子不能同时为哌啶基; 这些化合物的药学上可接受的盐以及这些化合物和这些盐的水合物具有中枢神经系统活性,特别是作为镇痛剂。